Cardiovascular efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: a systematic review and network meta‐analysis
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aims: To compare the cardiovascular efficacy and safety of sodium‐glucose co‐transporter‐2 ( SGLT 2) inhibitors and glucagon‐like peptide‐1 receptor agonists ( GLP ‐1 RA s) in adults with Type 2 diabetes. Methods: Electronic databases were searched from inception to 22 October 2018 for randomized controlled trials designed to assess the cardiovascular efficacy of SGLT 2 inhibitors or GLP ‐1 RA s with regard to a three‐point composite measure of major adverse cardiovascular events (non‐fatal stroke, non‐fatal myocardial infarction and cardiovascular mortality). Cardiovascular and safety data were synthesized using Bayesian network meta‐analyses. Results: Eight trials, including 60 082 participants, were deemed eligible for the network meta‐analysis. Both SGLT 2 inhibitors [hazard ratio 0.86 (95% credible interval 0.74, 1.01]) and GLP ‐1 RA s [hazard ratio 0.88 (95% credible interval 0.78, 0.98)] reduced the three‐point composite measure compared to placebo, with no evidence of differences between them [ GLP ‐1 RA s vs SGLT 2 inhibitors: hazard ratio 1.02 (95% credible interval 0.83, 1.23)]. SGLT 2 inhibitors reduced risk of hospital admission for heart failure compared to placebo [hazard ratio 0.67 (95% credible interval 0.53, 0.85)] and GLP ‐1 RA s [hazard ratio 0.71 (95% credible interval 0.53, 0.93)]. No differences were found between the two drug classes in non‐fatal stroke, non‐fatal myocardial infarction, cardiovascular mortality, all‐cause mortality or safety outcomes. Conclusions: SGLT 2 inhibitors and GLP ‐1 RA s reduced the three‐point major adverse cardiovascular event risk compared to placebo, with no differences between them. Compared with GLP ‐1 RA s and placebo, SGLT 2 inhibitors led to a larger reduction in hospital admission for heart failure risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 4×
“S1), resulting in seven reports (eight RCTs) included in the quantitative analysis (Table 1): EMPA-REG OUTCOME study [24]; CANVAS [25]; CANVAS-R [25]; ELIXA [26]; LEADER [27]; SUSTAIN-6 [28]; EXSCEL [29]; and the HARMONY study [30].”
BackgroundInfluentialSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Graphical tools for network meta-analysis in STATA
Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P., & Salanti, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076654 · Cited by 2,473
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 4×
“S1), resulting in seven reports (eight RCTs) included in the quantitative analysis (Table 1): EMPA-REG OUTCOME study [24]; CANVAS [25]; CANVAS-R [25]; ELIXA [26]; LEADER [27]; SUSTAIN-6 [28]; EXSCEL [29]; and the HARMONY study [30].”
BackgroundInfluentialHernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Dias, S., Sutton, A. J., Ades, A. E., & Welton, N. J. (2013) · Medical Decision Making · doi:10.1177/0272989x12458724 · Cited by 1,207
Diabetes and Decline in Heart Disease Mortality in US Adults
Gu, K. (1999) · JAMA · doi:10.1001/jama.281.14.1291 · Cited by 856
Research works printed but not linked: 30
- 10.1093/eurheartj/ehv239 · DOI · Paper page
- 10.1016/S2213-8587(14)70219-0 · DOI · Paper page
- 2018, Pharmacologic approaches to glycemic treatment: Standards of medical care in Diabetes ‐ 2018, American Diabetes Association. Diabetes Care, 41, S73
- 10.1016/j.phrs.2016.07.001 · DOI
- Tran KL, 2017, Overview of glucagon‐like peptide‐1 receptor agonists for the treatment of patients with type 2 diabetes, Am Health Drug Benefits, 10, 178
- 10.4158/CS-2017-0153 · DOI · Paper page
- 10.1016/S2213-8587(17)30412-6 · DOI · Paper page
- 10.1161/JAHA.117.007165 · DOI
- 10.1016/j.diabres.2018.03.027 · DOI · Paper page
- 10.1016/S2213-8587(16)00052-8 · DOI · Paper page
- 10.18549/PharmPract.2017.01.943 · DOI · Paper page
- 10.7326/M14-2385 · DOI · Paper page
- Shamseer L, 2015, Preferred reporting items for systematic review and meta‐analysis protocols (PRISMA‐P) 2015: elaboration and explanation, BMJ, 349
- 10.1111/dom.12849 · DOI · Paper page
- 10.7326/M15-1432 · DOI · Paper page
- 10.1111/dom.12670 · DOI · Paper page
- 10.1136/bmj.d5928 · DOI · Paper page
- 10.1056/NEJMoa1611925 · DOI · Paper page
- 10.1056/NEJMoa1612917 · DOI · Paper page
- 10.1186/s12933-017-0610-y · DOI
- 10.17925/EE.2017.13.02.86 · DOI
- 10.1016/S2213-8587(14)70031-2 · DOI · Paper page
- 10.1186/s12872-016-0260-0 · DOI
- 10.1016/j.jacc.2018.03.009 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.117.030012 · DOI · Paper page
- 10.1007/s11936-017-0522-x · DOI
- 10.1056/NEJMoa1812389 · DOI · Paper page
- 10.1001/jama.2018.3024 · DOI · Paper page
- 10.2337/dc17-0068 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.117.026229 · DOI
Cited by
Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
Clegg, L. E., Penland, R. C., Bachina, S., Boulton, D. W., Thuresson, M., Heerspink, H. J. L., Gustavson, S., Sjöström, C. D., Ruggles, J. A., Hernandez, A. F., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0942-x · Cited by 94
Hussein, H., Zaccardi, F., Khunti, K., Davies, M. J., Patsko, E., Dhalwani, N. N., Kloecker, D. E., Ioannidou, E., & Gray, L. J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14008 · Cited by 82
Self-citationNargesi, A. A., Jeyashanmugaraja, G. P., Desai, N., Lipska, K., Krumholz, H., & Khera, R. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021084 · Cited by 61
Masson, W., Lavalle-Cobo, A., Lobo, M., Masson, G., & Molinero, G. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa074 · Cited by 37
Metadata
- Authors
- Hussein, H., Zaccardi, F., Khunti, K., Seidu, S., Davies, M. J., & Gray, L. J.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2019-01-30
- Volume
- 36
- Issue
- 4
- Pages
- 444-452
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2910225231
- Cited by
- 43
- References
- 12
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- National Institute forHealth Research Collaborations for Leadership in AppliedHealthResearch and Care - EastMidlands
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: a systematic review and network meta‐analysis. https://app.cochat.ai/papers/10.1111/dme.13898
- The paper
- Hussein, H., Zaccardi, F., Khunti, K., Seidu, S., Davies, M. J., & Gray, L. J. (2019). Cardiovascular efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: a systematic review and network meta‐analysis. Diabetic Medicine. https://doi.org/10.1111/dme.13898
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.